FY21 results are in line with expectations, with the business laying the groundwork for market penetration and revenue growth. The D2C model was launched post-period end in Q1-22 and a strong pipeline of pharma co’s and patient advocacy groups are looking to sponsor access to the platform. The B2B contracting process continues to frustrate however, so management has refined its delivery model to enable faster customer acquisition with a more flexible cost base. In conjunction, planned expansion ....
10 May 2022
FY21 in line, strategy further refined
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY21 in line, strategy further refined
Trellus Health PLC (TRLS:LON) | 1.8 0 (-12.5%) | Mkt Cap: 2.83m
- Published:
10 May 2022 -
Author:
Chris Glasper -
Pages:
4
FY21 results are in line with expectations, with the business laying the groundwork for market penetration and revenue growth. The D2C model was launched post-period end in Q1-22 and a strong pipeline of pharma co’s and patient advocacy groups are looking to sponsor access to the platform. The B2B contracting process continues to frustrate however, so management has refined its delivery model to enable faster customer acquisition with a more flexible cost base. In conjunction, planned expansion ....